Stockscreener 앱 받기
2.86
7.44%
-0.23
시간 외 거래:
2.90
0.04
+1.40%
전일 마감가:
$3.09
열려 있는:
$3.12
하루 거래량:
3.24M
Relative Volume:
0.67
시가총액:
$305.41M
수익:
-
순이익/손실:
$-258.08M
주가수익비율:
-1.04
EPS:
-2.75
순현금흐름:
$-202.32M
1주 성능:
-4.35%
1개월 성능:
-3.38%
6개월 성능:
-72.34%
1년 성능:
-85.05%
1일 변동 폭
$2.835
$3.18
1주일 범위
$2.835
$3.18
52주 변동 폭
$2.19
$22.01
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
RCKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
2.86 | 325.37M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-30 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-05-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-28 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-28 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | 다운그레이드 | Needham | Buy → Hold |
| 2025-05-27 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
RCKT Deadline: RCKT Investors with Losses in Excess of $100K Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before August 11, 2025 to Discuss Your RightsRCKT - PR Newswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals - Bluefield Daily Telegraph
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT - GlobeNewswire Inc.
Has Rocket Pharmaceuticals Inc. Equity Warrant found a price floorFree Scalable Portfolio Growth Suggestions - Newser
Is Rocket Pharmaceuticals Inc. Equity Warrant forming a reversal patternReversal Signal Prediction Based on Volume - Newser
What high frequency data says about Rocket Pharmaceuticals Inc.Weekly Gain Forecast with Momentum Indicators - Newser
Will breakout in Rocket Pharmaceuticals Inc. lead to full recoveryProfit Target Planning with Exit Confidence - Newser
Faruqi & Faruqi Reminds Rocket Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025RCKT - PR Newswire
RCKT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class ActionRCKT - ACCESS Newswire
Rocket Pharmaceuticals and the Rocketing Risks in Biotech Innovation - AInvest
Faruqi & Faruqi Investigates Rocket Pharmaceuticals Securities Litigation - AInvest
Combining machine learning predictions for Rocket Pharmaceuticals Inc. Equity Warrant2-Day Signal Watch with Forecast Outcome - Newser
Should you wait for a breakout in Rocket Pharmaceuticals Inc.Profitable Trading Blueprint with Entry Zones - Newser
Custom watchlist performance reports with Rocket Pharmaceuticals Inc.Free Exit Ready Momentum Stock Watchlist - Newser
Rocket Pharmaceuticals Inc. Equity Warrant stock momentum explainedBreakout Watcher with Entry and Exit Alerts - Newser
Volume spikes in Rocket Pharmaceuticals Inc. stock – what they meanSafe Entry Screening with Data Backed Analysis - Newser
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT)Join by August 11, 2025Contact Levi & Korsinsky - Stockhouse
Class Action Filed Against Rocket Pharmaceuticals, Inc. - GlobeNewswire
Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors – Contact Levi & Korsinsky - Morningstar
Rocket Pharmaceuticals and the Biotech Litigation Landscape: Navigating Risks in a High-Stakes Sector - AInvest
August 11, 2025 Deadline: Join Class Action Lawsuit Against Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky - Barchart.com
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class - GlobeNewswire
Rocket Pharmaceuticals stock price target raised to $3.00 from $2.50 at Jefferies - Investing.com Canada
Rocket Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
2025-08-07 | Securities Class Action Lawsuit Filed Against Rocket Pharmaceuticals, Inc. (RCKT)Levi & Korsinsky Represents Shareholders | NDAQ:RCKT | Press Release - Stockhouse
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd - GlobeNewswire
Rocket Pharmaceuticals Announces Strategic Restructuring and Leadership Changes - TipRanks
Investors in Rocket Pharmaceuticals, Inc. Should Contact - GlobeNewswire
Rocket Pharmaceuticals, Inc. Investors: Please contact the - GlobeNewswire
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress | RCKT Stock News - GuruFocus
Rocket (RCKT) Q2 Loss Narrows 16% - Nasdaq
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
RCKT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, - GlobeNewswire
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) - GlobeNewswire
Lost Money on Rocket Pharmaceuticals, Inc.(RCKT)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - Morningstar
Tools to monitor Rocket Pharmaceuticals Inc. Equity Warrant recovery probabilityLow Drawdown Picks with Weekly Updates - Newser
2025-08-06 | Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action | NDAQ:RCKT | Press Release - Stockhouse
Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 - Barchart.com
Berger Montague Reminds Rocket Pharmaceuticals (RCKT) Investors With Substantial Losses to Inquire About a Securities Fraud Class Action by August 11, 2025 - TradingView
Rocket Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your RightsRCKT - NewMediaWire
Universal Beteiligungs und Servicegesellschaft mbH Invests $143,000 in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Shareholders of Rocket Pharmaceuticals, Inc. Should Contact - GlobeNewswire
Rocket Pharmaceuticals, Inc. (RCKT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 11, 2025 Deadline - ACCESS Newswire
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Evaluating Rocket Pharmaceuticals Inc. Equity Warrant with trendline analysisLow Risk Trade Timing with Analysis Metrics - Newser
DEADLINE NEXT WEEK: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - PR Newswire
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):